Developer docs
API playgroundTry for free, no card

Search company profiles

NeuroSpa TMS

Full company profile

uuid0008elb

Namestring
NeuroSpa TMS
Websiteurl
neurospatms.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

NeuroSpa TMS is a private, Tampa-based interventional psychiatry clinic operator founded in 2018 that delivers pill-free, FDA-approved Transcranial Magnetic Stimulation (TMS) therapy to patients with treatment-resistant depression, PTSD, and suicidality. The company positions its clinics in a spa-like setting and concentrates exclusively on the interventional psychiatry use case, vertically segmented for patients who have not responded to conventional treatments. No proprietary technology stack beyond standard TMS devices is described in available sources, and pricing is not publicly disclosed.

The business model is service-based: revenue is generated per TMS procedure across a growing clinic footprint, with go-to-market executed through direct clinic operations and a network build-out strategy in Florida. Following a Dura Medical acquisition referenced in the dataset, the network has scaled to 8+ interventional psychiatry clinic locations in the state. A strategic partnership with Ampa Health, announced in November 2025, has introduced a first-in-Florida "one-day" depression treatment offering and integrates the clinic network with NRx Pharmaceuticals' pharmaceutical protocols through the broader HOPE Therapeutics ecosystem.

Strategically, NeuroSpa TMS sits within a depression treatment market projected to expand to $750M-$3.35B by 2034. Competitive positioning rests on clinical delivery, regional density in Florida, and bundled pharmaceutical-device protocols rather than software or AI-driven differentiation. Inputs on ownership, management team, financials, and formal corporate linkage to NRx/HOPE Therapeutics remain data gaps in the available sources.

Short descriptiontext

NeuroSpa TMS is a Florida-based, private interventional psychiatry clinic network founded in 2018 that delivers FDA-approved Transcranial Magnetic Stimulation (TMS) therapy to patients with treatment-resistant depression, PTSD, and suicidality across 8+ clinic locations.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTampa, United States
HQ citystring
Tampa
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
TMS depression treatment, transcranial magnetic stimulation, mental health services, treatment-resistant depression, interventional psychiatry
Industry3 codes
1Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
CodeHLAHAEAKPrimaryYes
2Psychiatry & Medication Management Platforms
CodeHLALAEABPrimaryNo
3Behavioral Health & Neurocognitive Therapeutics (Digital)
CodeHLACANAIPrimaryNo
NAICS code2 codes
  • Offices of Physicians, Mental Health Specialists621112
  • Outpatient Mental Health and Substance Abuse Centers62142
SIC code1 code
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Mental Health Services
No data
Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

NeuroSpa TMS delivers Transcranial Magnetic Stimulation (TMS) therapy for patients with depression, PTSD, and suicidality in spa-like clinical settings. Treatment is FDA-approved, pill-free, and non-invasive, with the company operating 8 or more Florida locations. The company also offers a one-day depression treatment protocol through a partnership with Ampa Health and has expanded its footprint by acquiring Dura Medical.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Expanding to 8+ interventional psychiatry clinic locations in Florida
Product overview1 text field

No product or service information available from the source data. The NeuroSpa TMS website (neurospatms.com) displayed only a loading/verification page without accessible content. The news sources reference TMS-related depression treatments in the broader healthcare industry but do not provide specific information about NeuroSpa TMS's own product portfolio, services, or offerings.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Ampa Health
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-10
Description

Ampa Health partnered with NRx Pharmaceuticals to launch the first-in-Florida 'One Day' depression treatment. This partnership leverages Ampa Health's healthcare delivery capabilities with NRx's pharmaceutical offerings to provide rapid depression treatment in Florida.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1TMS NeuroHealth Centers
TypeDirect peer
Description

Specialty TMS clinic group focused on treatment-resistant depression and related behavioral health conditions; directly comparable service line and patient population to NeuroSpa.

2Field Trip Health
TypeDirect peer
Description

Clinic network delivering interventional psychiatry (ketamine, TMS) for depression and PTSD; comparable interventional psychiatry clinic model.

3Cerebral
TypeBroad incumbent
Description

Large behavioral health platform addressing depression and anxiety; competes for the same patient population but primarily via telehealth and medication management.

4Talkiatry
TypeBroad incumbent
Description

Tech-enabled outpatient psychiatry group (and acquirer of Greenbrook TMS); competes for the same patient population, albeit with a primarily telehealth-first delivery model.

5Success TMS
TypeDirect peer
Description

Multi-state TMS treatment provider for depression, anxiety, and PTSD; closely comparable specialty clinic model and patient demographic.

6MindPath Care Centers
TypeDirect peer
Description

Outpatient psychiatry group offering TMS alongside therapy and medication management; comparable multi-site interventional psychiatry model, though with broader service mix.

7Bespoke Treatment
TypeEmerging player
Description

Interventional psychiatry practice offering TMS, ketamine, and SPRAVATO; overlaps with NeuroSpa on interventional modalities for treatment-resistant depression.

8Greenbrook TMS
TypeDirect peer
Description

Multi-site TMS clinic network treating depression and OCD; the most direct operating-model comparable to NeuroSpa's interventional psychiatry clinic footprint.

9Pasadena Recovery Center
TypeRegional player
Description

Regional behavioral health provider offering psychiatric services including TMS-adjacent modalities; comparable patient base but different geographic market.

10NRx Pharmaceuticals
TypeOthers
Description

Partner/strategic counterparty of NeuroSpa-affiliated clinics via Ampa Health; relevant as a pharmaceutical partner for the 'One Day' depression protocol rather than a direct competitor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuroSpa TMS

Mental Health Servicesneurospatms.com

NeuroSpa TMS is a Florida-based, private interventional psychiatry clinic network founded in 2018 that delivers FDA-approved Transcranial Magnetic Stimulation (TMS) therapy to patients with treatment-resistant depression, PTSD, and suicidality across 8+ clinic locations.

What NeuroSpa TMS does

NeuroSpa TMS is a private, Tampa-based interventional psychiatry clinic operator founded in 2018 that delivers pill-free, FDA-approved Transcranial Magnetic Stimulation (TMS) therapy to patients with treatment-resistant depression, PTSD, and suicidality. The company positions its clinics in a spa-like setting and concentrates exclusively on the interventional psychiatry use case, vertically segmented for patients who have not responded to conventional treatments. No proprietary technology stack beyond standard TMS devices is described in available sources, and pricing is not publicly disclosed.

The business model is service-based: revenue is generated per TMS procedure across a growing clinic footprint, with go-to-market executed through direct clinic operations and a network build-out strategy in Florida. Following a Dura Medical acquisition referenced in the dataset, the network has scaled to 8+ interventional psychiatry clinic locations in the state. A strategic partnership with Ampa Health, announced in November 2025, has introduced a first-in-Florida "one-day" depression treatment offering and integrates the clinic network with NRx Pharmaceuticals' pharmaceutical protocols through the broader HOPE Therapeutics ecosystem.

Strategically, NeuroSpa TMS sits within a depression treatment market projected to expand to $750M-$3.35B by 2034. Competitive positioning rests on clinical delivery, regional density in Florida, and bundled pharmaceutical-device protocols rather than software or AI-driven differentiation. Inputs on ownership, management team, financials, and formal corporate linkage to NRx/HOPE Therapeutics remain data gaps in the available sources.

NeuroSpa TMS firmographics

Firmographics
Name
NeuroSpa TMS
Website
https://neurospatms.com
Company type
Private
Founded year
2018
Headcount range
11–50 employees
Short description
NeuroSpa TMS is a Florida-based, private interventional psychiatry clinic network founded in 2018 that delivers FDA-approved Transcranial Magnetic Stimulation (TMS) therapy to patients with treatment-resistant depression, PTSD, and suicidality across 8+ clinic locations.
Ownership category
akta.pro rank

NeuroSpa TMS industry classification

Industry
Product category
Mental Health Services
NAICS
Offices of Physicians, Mental Health Specialists (621112), Outpatient Mental Health and Substance Abuse Centers (62142)
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro primary industry
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
akta.pro secondary industries
Psychiatry & Medication Management Platforms (HLALAEAB), Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

Keywords

  • TMS depression treatment
  • Transcranial magnetic stimulation
  • Mental health services
  • Treatment-resistant depression
  • Interventional psychiatry

Where NeuroSpa TMS is headquartered

Location

Headquarters

HQ city
Tampa
HQ country
United States
HQ region
North America

Markets served

NeuroSpa TMS business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

NeuroSpa TMS product offering

Product offering

Core offering

NeuroSpa TMS delivers Transcranial Magnetic Stimulation (TMS) therapy for patients with depression, PTSD, and suicidality in spa-like clinical settings. Treatment is FDA-approved, pill-free, and non-invasive, with the company operating 8 or more Florida locations. The company also offers a one-day depression treatment protocol through a partnership with Ampa Health and has expanded its footprint by acquiring Dura Medical.

Product overview

No product or service information available from the source data. The NeuroSpa TMS website (neurospatms.com) displayed only a loading/verification page without accessible content. The news sources reference TMS-related depression treatments in the broader healthcare industry but do not provide specific information about NeuroSpa TMS's own product portfolio, services, or offerings.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Expanding to 8+ interventional psychiatry clinic locations in Florida

Companies that use NeuroSpa TMS

Customer profile

Segments1 record

Ideal customer profiles1 record

NeuroSpa TMS technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

NeuroSpa TMS partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ampa HealthcoreStrategic or Co-development Partner · 10 November 2025Ampa Health partnered with NRx Pharmaceuticals to launch the first-in-Florida 'One Day' depression treatment. This partnership leverages Ampa Health's healthcare delivery capabilities with NRx's pharmaceutical offerings to provide rapid depression treatment in Florida.

Scale indicators2 records

Recent moves4 records

Expansion highlights5 records

NeuroSpa TMS competitors and assessment

Company assessment

Direct peers

  • TMS NeuroHealth Centers: Specialty TMS clinic group focused on treatment-resistant depression and related behavioral health conditions; directly comparable service line and patient population to NeuroSpa.
  • Field Trip Health: Clinic network delivering interventional psychiatry (ketamine, TMS) for depression and PTSD; comparable interventional psychiatry clinic model.
  • Success TMS: Multi-state TMS treatment provider for depression, anxiety, and PTSD; closely comparable specialty clinic model and patient demographic.
  • MindPath Care Centers: Outpatient psychiatry group offering TMS alongside therapy and medication management; comparable multi-site interventional psychiatry model, though with broader service mix.
  • Greenbrook TMS: Multi-site TMS clinic network treating depression and OCD; the most direct operating-model comparable to NeuroSpa's interventional psychiatry clinic footprint.

Broad incumbents

  • Cerebral: Large behavioral health platform addressing depression and anxiety; competes for the same patient population but primarily via telehealth and medication management.
  • Talkiatry: Tech-enabled outpatient psychiatry group (and acquirer of Greenbrook TMS); competes for the same patient population, albeit with a primarily telehealth-first delivery model.

Emerging players

  • Bespoke Treatment: Interventional psychiatry practice offering TMS, ketamine, and SPRAVATO; overlaps with NeuroSpa on interventional modalities for treatment-resistant depression.

Regional players

  • Pasadena Recovery Center: Regional behavioral health provider offering psychiatric services including TMS-adjacent modalities; comparable patient base but different geographic market.

Others

  • NRx Pharmaceuticals: Partner/strategic counterparty of NeuroSpa-affiliated clinics via Ampa Health; relevant as a pharmaceutical partner for the 'One Day' depression protocol rather than a direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

NeuroSpa TMS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuroSpa TMS leadership team

Management profile

Number of profiles

NeuroSpa TMS funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuroSpa TMS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroSpa TMS

What does NeuroSpa TMS do?

NeuroSpa TMS delivers Transcranial Magnetic Stimulation (TMS) therapy for patients with depression, PTSD, and suicidality in spa-like clinical settings. Treatment is FDA-approved, pill-free, and non-invasive, with the company operating 8 or more Florida locations. The company also offers a one-day depression treatment protocol through a partnership with Ampa Health and has expanded its footprint by acquiring Dura Medical.

Is NeuroSpa TMS a public or private company?

NeuroSpa TMS is a private company. It is classified as unknown.

When was NeuroSpa TMS founded?

NeuroSpa TMS was founded in 2018. It employs 11 to 50 people.

Where is NeuroSpa TMS based?

NeuroSpa TMS is headquartered in Tampa, United States, in the North America region.

Who are NeuroSpa TMS's main competitors?

Direct peers on record are TMS NeuroHealth Centers, Field Trip Health, Success TMS, MindPath Care Centers and Greenbrook TMS. Broad incumbents are Cerebral and Talkiatry. Bespoke Treatment is listed as an emerging player. Pasadena Recovery Center is listed as a regional player. NRx Pharmaceuticals is listed as an others.

Does NeuroSpa TMS have an API?

No public API is recorded for NeuroSpa TMS.

What industry is NeuroSpa TMS in?

NeuroSpa TMS's product category is Mental Health Services. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLALAEAB, Psychiatry & Medication Management Platforms. Its NAICS code is 621112 and its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry ClinicsHOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, closed its acquisition of Dura Medical, a Florida-based interventional psychiatry clinic. Dura, which is revenue-generating and EBITDA-positive, will operate with HOPE at over 8 locations along Florida's West Coast. The combined network aims to treat more than 10,000 people by 2026.PR NewswireHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of IHOPE Therapeutics, Inc., a wholly owned subsidiary of NRx Pharmaceuticals, announced signing a binding Letter of Intent to acquire a majority interest in Neurospa TMS Holdings, LLC, which operates six interventional psychiatry clinics on Florida's Gulf Coast. Neurospa provides treatments including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation, and Spravato for patients with depression, suicidality, PTSD, and related disorders, and is described as revenue generating and EBITDA positive. The acquisition, subject to completion of financial audits and standard closing conditions, is expected to be accretive to HOPE's 2025 revenue projections and will serve as a key element of HOPE's planned Florida network expansion.